Eli Lilly’s retatrutide weight loss trial has delivered some of the strongest obesity treatment results ever reported in a late-stage clinical study. The company announced that patients taking the highest dose of retatrutide lost an average of 28.3% of their body weight over 80 weeks, a level of weight reduction often associated with bariatric surgery.
The findings come from TRIUMPH-1, Lilly’s Phase 3 obesity study involving more than 2,300 adults living with obesity or overweight and at least one weight-related health condition. The trial marks a major milestone for the pharmaceutical company as competition intensifies in the rapidly growing obesity drug market.
According to Eli Lilly and Company, participants receiving the 12 mg dose lost an average of 70.3 pounds, while nearly 45% achieved at least 30% weight loss. Researchers also reported improvements in cardiometabolic markers, including blood pressure, waist circumference, and cholesterol levels.
How Is Retatrutide Weight Loss Drug Different From Others?
Retatrutide is being described as one of the next-generation obesity drugs because it targets three hormone pathways linked to appetite and metabolism.
The weekly injection activates:
- GLP-1 receptors, which help reduce appetite
- GIP receptors, which improve insulin response
- Glucagon receptors, which may increase fat burning
This “triple agonist” approach differs from existing obesity medications such as Zepbound and Wegovy, which target one or two pathways instead of three.
Experts believe this obesity drug combination may explain the unusually high levels of weight reduction seen in the study.
Dan Skovronsky, Lilly’s chief scientific officer, said that the 30% weight loss range was “an incredible number to see” because it has historically been associated with surgical procedures rather than medication.
Key Results From Eli Lilly’s Retatrutide Weight Loss Trial
The retatrutide trial results showed significant benefits across multiple dosage levels.
Major Findings From the Study
- 28.3% average weight loss at the 12 mg dose
- 25.9% average weight loss at the 9 mg dose
- 19% average weight loss at the 4 mg dose
- Nearly 65% of participants on the highest dose moved below the obesity BMI threshold
Patients with severe obesity who continued treatment for 104 weeks lost up to 30.3% of body weight.
Researchers noted that the lower 4 mg dose of the retatrutide obesity drug also produced strong outcomes while showing fewer treatment discontinuations due to side effects.
Safety Findings & Side Effects From Lily’s Retatrutide Trial
Like many GLP-1-based obesity treatments, the retatrutide obesity injection was associated mainly with gastrointestinal side effects.
The most commonly reported side effects included:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Upper respiratory infections
The retatrutide trial also recorded cases of dysesthesia, an unpleasant nerve sensation, and slightly higher rates of urinary tract infections. However, Lilly stated that most side effects were mild to moderate and generally manageable. Importantly, the company reported no major cardiac or liver safety concerns during the study.
How Eli Lilly’s New Trial Can Shift the Obesity Drug Market
The Retatrutide drug trial results strengthen Lilly’s position in the expanding obesity treatment sector, which is estimated to become a $100 billion global market within the next decade.
The company already markets Zepbound and recently launched Foundayo. Retatrutide could become another major product in Lilly’s obesity portfolio if it receives FDA drug approval. The drug also intensifies competition with Novo Nordisk, maker of Wegovy and Ozempic, especially as drugmakers race to develop more effective therapies for chronic weight management.
What Happens Next for Lilly’s Retatrutide?
Lilly said additional data from the TRIUMPH clinical trial program will be released later this year, including studies focused on type 2 diabetes and cardiovascular disease.
The company is also studying retatrutide for conditions such as:
- Obstructive sleep apnea
- Osteoarthritis pain
- Fatty liver disease
- Chronic low back pain
Lilly hopes to seek regulatory approval and potentially launch the drug next year.
For healthcare experts and patients, Eli Lilly’s retatrutide weight loss trial may represent a major turning point in obesity care. While long-term safety, affordability, and access remain important questions, the Phase 3 results suggest the future of obesity treatment could move far beyond what current medications can achieve.
